These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 31770193)

  • 21. Cost utility of tumour necrosis factor-α inhibitors for rheumatoid arthritis: an application of Bayesian methods for evidence synthesis in a Markov model.
    Nguyen CM; Bounthavong M; Mendes MA; Christopher ML; Tran JN; Kazerooni R; Morreale AP
    Pharmacoeconomics; 2012 Jul; 30(7):575-93. PubMed ID: 22640174
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized, controlled trial of efficacy and safety of Anbainuo, a bio-similar etanercept, for moderate to severe rheumatoid arthritis inadequately responding to methotrexate.
    Chen XX; Li ZG; Wu HX; Zhao DB; Li XF; Xu JH; Tao Y; Yang NP; Hu SX; Huang AB; Jiang LD; Wang GC; Zhang X; Bao CD
    Clin Rheumatol; 2016 Sep; 35(9):2175-83. PubMed ID: 27184046
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The economic burden of biological therapy in rheumatoid arthritis in clinical practice: cost-effectiveness analysis of sub-cutaneous anti-TNFalpha treatment in Italian patients.
    Benucci M; Li Gobbi F; Sabadini L; Saviola G; Baiardi P; Manfredi M
    Int J Immunopathol Pharmacol; 2009; 22(4):1147-52. PubMed ID: 20074482
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-Utility Analysis of TNF-α Inhibitors, B Cell Inhibitors, and JAK Inhibitors Versus csDMARDs for Rheumatoid Arthritis Treatment.
    Haridoss M; Sasidharan A; Kumar S; Rajsekar K; Venkataraman K; Bagepally BS
    Appl Health Econ Health Policy; 2024 Nov; 22(6):885-896. PubMed ID: 38951442
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-Effectiveness Analysis of Abatacept Compared with Adalimumab on Background Methotrexate in Biologic-Naive Adult Patients with Rheumatoid Arthritis and Poor Prognosis.
    Alemao E; Johal S; Al MJ; Rutten-van Mölken M
    Value Health; 2018 Feb; 21(2):193-202. PubMed ID: 29477401
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity.
    Prawjaeng J; Leelahavarong P; Budtarad N; Pilasant S; Chanjam C; Katchamart W; Narongroeknawin P; Kitumnuaypong T
    BMC Health Serv Res; 2023 May; 23(1):561. PubMed ID: 37259090
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate.
    Vera-Llonch M; Massarotti E; Wolfe F; Shadick N; Westhovens R; Sofrygin O; Maclean R; Yuan Y; Oster G
    Rheumatology (Oxford); 2008 Apr; 47(4):535-41. PubMed ID: 18356179
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness Analysis of Treatment Sequence Initiating With Etanercept Compared With Leflunomide in Rheumatoid Arthritis: Impact of Reduced Etanercept Cost With Patent Expiration in South Korea.
    Park SK; Park SH; Lee MY; Park JH; Jeong JH; Lee EK
    Clin Ther; 2016 Nov; 38(11):2430-2446.e3. PubMed ID: 27771177
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modeling and cost-effectiveness analysis of etanercept in adults with rheumatoid arthritis in Japan: a preliminary analysis.
    Tanno M; Nakamura I; Ito K; Tanaka H; Ohta H; Kobayashi M; Tachihara A; Nagashima M; Yoshino S; Nakajima A
    Mod Rheumatol; 2006; 16(2):77-84. PubMed ID: 16633926
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Certolizumab Pegol for Treating Rheumatoid Arthritis Following Inadequate Response to a TNF-α Inhibitor: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Bermejo I; Stevenson M; Archer R; Stevens JW; Goka E; Clowes M; Scott DL; Young A
    Pharmacoeconomics; 2017 Nov; 35(11):1141-1151. PubMed ID: 28550592
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-Effectiveness of Biosimilars vs Leflunomide in Patients With Rheumatoid Arthritis.
    Peng K; Chan SCW; Wang Y; Cheng FWT; Yeung WWY; Jiao Y; Chan EWY; Wong ICK; Lau CS; Li X
    JAMA Netw Open; 2024 Jun; 7(6):e2418800. PubMed ID: 38922614
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Health-economic assessment of combination therapy for rheumatoid arthritis with methotrexat and etanercept based on the TEMPO Study].
    Schulze-Koops H; Deeg M; Runge C; Volmer T; Brecht JG
    Z Rheumatol; 2009 Dec; 68(10):836-41. PubMed ID: 19756664
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Best cost-effectiveness and worker productivity with initial triple DMARD therapy compared with methotrexate monotherapy in early rheumatoid arthritis: cost-utility analysis of the tREACH trial.
    de Jong PH; Hazes JM; Buisman LR; Barendregt PJ; van Zeben D; van der Lubbe PA; Gerards AH; de Jager MH; de Sonnaville PB; Grillet BA; Luime JJ; Weel AE
    Rheumatology (Oxford); 2016 Dec; 55(12):2138-2147. PubMed ID: 27581208
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis: a cost-effectiveness analysis compared with adalimumab in Taiwan.
    Chen DY; Hsu PN; Tang CH; Claxton L; Valluri S; Gerber RA
    J Med Econ; 2019 Aug; 22(8):777-787. PubMed ID: 30982378
    [No Abstract]   [Full Text] [Related]  

  • 35. Cost-effectiveness analysis of upadacitinib as a treatment option for patients with rheumatoid arthritis in the Kingdom of Saudi Arabia.
    Al-Abdulkarim H; Sharma Y; Attar SM; Husain W; Al-Homood I; Al Omari B; Mohamed O; Alsaqa'aby M; Jaheen AM; Anwar A; Hamad TM; Alzahrani Z
    J Med Econ; 2024; 27(1):134-144. PubMed ID: 38163926
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Economic Evaluation of Sarilumab in the Treatment of Adult Patients with Moderately-to-Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs.
    Muszbek N; Proudfoot C; Fournier M; Chen CI; Kuznik A; Kiss Z; Gal P; Michaud K
    Adv Ther; 2019 Jun; 36(6):1337-1357. PubMed ID: 31004324
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, versus methotrexate in patients with rheumatoid arthritis using real-world data from the IORRA observational cohort study.
    Tanaka E; Inoue E; Hoshi D; Shimizu Y; Kobayashi A; Sugimoto N; Shidara K; Sato E; Seto Y; Nakajima A; Momohara S; Taniguchi A; Yamanaka H
    Mod Rheumatol; 2015 Jul; 25(4):503-13. PubMed ID: 25547018
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis.
    Tang B; Rahman M; Waters HC; Callegari P
    Clin Ther; 2008 Jul; 30(7):1375-84. PubMed ID: 18691998
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modelling the cost-effectiveness of combination therapy for early, rapidly progressing rheumatoid arthritis by simulating the reversible and irreversible effects of the disease.
    Stephens S; Botteman MF; Cifaldi MA; van Hout BA
    BMJ Open; 2015 Jun; 5(6):e006560. PubMed ID: 26059521
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
    Brown S; Everett CC; Naraghi K; Davies C; Dawkins B; Hulme C; McCabe C; Pavitt S; Emery P; Sharples L; Buch MH
    Health Technol Assess; 2018 Jun; 22(34):1-280. PubMed ID: 29900829
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.